The ruling comes amid major shifts in the national firearm legal landscape following a landmark U.S. Supreme Court decision that expanded gun rights in 2022.
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback